MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Patient case reports supporting a long-term effect of sub-anesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias

S.J. Sherman, T. Falk (Tucson, AZ, USA)

Meeting: 2016 International Congress

Abstract Number: 1951

Keywords: Depression, Motor cortex, NMDA, Pain

Session Information

Date: Thursday, June 23, 2016

Session Title: Parkinson's disease: Clinical trials, pharmacology and treatment

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To evaluate possible long-term anti-dyskinetic activity of low-dose sub-anesthetic ketamine infusion from a retrospective chart review.

Background: Repurposing drugs that have already been proven safe in humans has the potential to offer new therapies at a fraction of the time required to develop new drug treatments. Low-dose sub-anesthetic ketamine infusion treatment has led to long-term reduction of chronic pain states, including migraine headaches, and to reduction of treatment-resistant depression and posttraumatic stress disorder (PTSD) symptom severity. Ketamine also is known to change oscillatory electric brain activity. One commonality between migraine headaches, depression, PTSD, Parkinson’s disease (PD) and L-DOPA-induced dyskinesia (LID) is hypersynchrony of electric activity in the brain, including the basal ganglia. An effective treatment of LID to extend the useful lifetime of L-DOPA treatment is a critical unmet need in PD therapy.

Methods: We investigated the use of low-dose ketamine in the treatment of PD and LID from a retrospective chart review. Patients were treated in the intensive care unit using a protocol for treatment of intractable pain that specified titration of ketamine to a target rate of 0.15 – 0.3 mg/kg/hr for 50 – 96 hr periods.

Results: There was a long-term therapeutic effect of sub-anesthetic ketamine infusion from five PD patient case studies identified by a retrospective chart review (reduced dyskinesia, reduced pain, improved on time, and reduced depression). There was no significant sedation in any of the cases. A separate abstract presented at this meeting explores mechanisms involved in a rodent preclinical model (Falk, Bartlett, Ye, Lazarus, Heien, Cowen, Sherman; Preclinical evaluation of sub-anesthetic ketamine infusion to reduce L-DOPA-induced dyskinesias: is it a ‘chemical’ DBS?).

Conclusions: This novel use of low-dose sub-anesthetic ketamine infusion could lead to rapid clinical translation for the treatment of dyskinesia. Since comorbid pain states and depression are critical problems for many Parkinson’s disease patients, ketamine could be developed as a multi-faceted treatment.

American Neurological Association Meeting 2015, Chicago.

To cite this abstract in AMA style:

S.J. Sherman, T. Falk. Patient case reports supporting a long-term effect of sub-anesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/patient-case-reports-supporting-a-long-term-effect-of-sub-anesthetic-ketamine-infusion-in-reducing-l-dopa-induced-dyskinesias/. Accessed May 24, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/patient-case-reports-supporting-a-long-term-effect-of-sub-anesthetic-ketamine-infusion-in-reducing-l-dopa-induced-dyskinesias/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley